A5066245688- Antibiotic Use and Resistance
- Antibiotic Resistance in Bacteria
- Clostridium difficile and Clostridium perfringens research
- Pneumonia and Respiratory Infections
- Antibiotics Pharmacokinetics and Efficacy
- Antimicrobial Resistance in Staphylococcus
- Microscopic Colitis
- Bacterial Identification and Susceptibility Testing
- Nosocomial Infections in ICU
- Gut microbiota and health
- Respiratory and Cough-Related Research
- Gastrointestinal motility and disorders
- Tuberculosis Research and Epidemiology
- Urinary Tract Infections Management
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Cystic Fibrosis Research Advances
- Bacterial Infections and Vaccines
- Respiratory viral infections research
- Health Systems, Economic Evaluations, Quality of Life
- Streptococcal Infections and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Mycobacterium research and diagnosis
- Drug-Induced Adverse Reactions
- Chronic Obstructive Pulmonary Disease (COPD) Research
MP Technologies (United States)
2019-2024
Infectious Disease Consultants
2023
Sigma Theta Tau International
2022
University of Kentucky
2022
The Society for Post-Acute and Long-Term Care Medicine
2022
Centers for Medicare and Medicaid Services
2022
American Medical Association
2022
Bayer (Germany)
1995-2022
Mayo Clinic in Florida
2022
Cempra Pharmaceuticals (United States)
2012-2020
The dwindling supply of new antibiotics largely reflects regulatory and commercial challenges, but also a failure discovery. In the 1990s pharmaceutical industry abandoned its classical ways seeking instead adopted strategy that combined genomics with high-throughput screening existing compound libraries. Too much emphasis was placed on identifying targets molecules bound to them, too little ability these permeate bacteria, evade efflux avoid mutational resistance; moreover, libraries were...
Microbial communities play a significant role in maintaining ecosystems healthy homeostasis. Presently, the human gastrointestinal tract, there are certain taxonomic groups of importance, though is no single species that plays keystone role. Bacteroides spp. known to be major players maintenance eubiosis tract. Here we review critical gut, their potential pathogenic outside and various methods adapting environment, with focus on data for B. fragilis thetaiotaomicron. anaerobic non-sporing...
We evaluated the annual rate (cases/10,000 hospitalizations) of pediatric hospitalizations with Clostridium difficile infection (CDI; International Classification Diseases, 9th revision, clinical modification code 008.45) in United States. performed a time-series analysis data from Kids' Inpatient Database within Health Care Cost and Utilization Project during 1997-2006 cross-sectional National Hospital Discharge Survey 2006. The CDI-related increased 7.24 to 12.80 1997 through 2006; lowest...
Patients with an acute infective exacerbation of chronic bronchitis (AECB) (n = 471) were enrolled into a computer-based general-practice study to determine whether features past history, presenting symptoms, or findings on examination predictive failure recover. The median age was 68, 56.3% male, and 82% current ex-smokers. All had daily sputum production 57.5% moderate severe airflow obstruction. During the AECB 11.5% pyrexial, 80.7% abnormal auscultatory findings; about half increases in...
Clostridium difficile infection is the most common health-care-associated in USA. We assessed safety and efficacy of ridinilazole versus vancomycin for treatment C infection.We did a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Participants with signs symptoms positive diagnostic test result were recruited from 33 centres USA Canada randomly assigned (1:1) to receive oral (200 mg every 12 h) or (125 6 10 days. The primary endpoint was achievement sustained...
Antimicrobial resistance has become a global problem. Many pathogens are becoming multidrug-resistant with the attendant increased risk of failure standard therapies and under-recognised outcomes such as morbidity, mortality, length hospitalization costs treatment. Areas covered: We undertook review literature using search engines including PubMed, Google Scholar, Scopus internet sources. Key terms included antimicrobial resistance, antibiotic bacterial clinical outcomes, economic...
Abstract Background Recurrence of Clostridioides difficile infection (rCDI) is common, prolonging disease morbidity and leading to poor quality life. We evaluated disease-specific health-related life (HRQL) in patients with rCDI treated fecal microbiota, live-jslm (REBYOTA [RBL]; Rebiotix) versus placebo. Methods This was a secondary analysis randomized, double-blind, placebo-controlled phase 3 study (PUNCH CD3). The Quality Life Survey (Cdiff32) administered at baseline weeks 1, 4, 8....
The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry encourage development new antibacterial molecules related diagnostics has been compromised by increasing costs regulatory hurdles, resulting in a decreasing chance success financial return. supply effective agents is diminishing along with number companies engaged research development. BSAC Working Party Urgent Need:Regenerating Antibacterial Drug Discovery...
Stenotrophomonas maltophilia is an opportunistic pathogen observed in both nosocomial and community-onset infections. S. intrinsically resistant to many currently available broad-spectrum antibiotics often not included antimicrobial resistance surveillance studies or stewardship programs' guidelines.A retrospective cohort study of patients with bloodstream infection (BSI) the United States was conducted using 2010-2015 US Premier Healthcare Database. This described patient characteristics,...
Abstract: Clostridioides difficile infection (CDI) remains a significant contributor to healthcare costs and morbidity due high rates of recurrence. Currently, available antibiotic treatment strategies further disrupt the fecal microbiome do not address alterations in commensal flora (dysbiosis) that set stage for CDI. Advances microbiome-based research have resulted development new agents, classified as live biotherapeutic products (LBPs), preventing recurrent CDI (rCDI) by restoring...
Abstract Background Fecal microbiota, live-jslm (RBL; Rebyota), is the first Food and Drug Administration–approved, single-dose, microbiota–based live biotherapeutic to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Patients who are immunocompromised often considered at higher risk for C infection, including recurrence, as compared with those immunocompetent. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated RBL...
The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a regimen (HRC) consisting isoniazid (300 rng), rifampin (600 mg), and ciprofloxacin (750 mg) or control (HRZE) pyrazinamide (25 mg/kg), ethambutol (15 mg/kg). 168 evaluable all had negative smears cultures by month 6, but the time to conversion negativity longer for HRC group...
Hereditary angioedema (HAE) is a rare inherited disorder of complement factor C1 inhibitor. HAE frequently confused with (AE), and little known about emergency department (ED) or hospital utilization by patients attacks in the United States. We examined hospitalizations ED for AE two large nationally representative databases. evaluated annual rate resource use (International Classification Diseases, Version 9, Clinical Modification [ICD-9-CM] code 277.6) (ICD-9-CM 995.1) within Nationwide...